CA
NZ
UK
AU
IND
US
• First-quarter earnings per share reached $2.70 on revenue of $24.06 billion, up 9.9% year over year.
• The company reported securing lower raw material prices from suppliers to stay competitive in the weight-loss drug market.
• The stock remains roughly 68% below its May registered-direct offering price of $20.30.
• VERAXA Biotech (NASDAQ:VRXA) has initiated cell line development for its lead BiTAC-TCE program in collaboration with ATUM.
• Two Very Different Scientific Approaches: Elicio's ELI-002 7P is an immune-activating cancer vaccine while Revolution Medicines' daraxonrasib is a direct small molecule RAS inhibitor targeting the same disease.
• Two Distinct Isotope Approaches: Telix uses lutetium-177 (beta emitter) in prostate cancer while Molecular Partners employs lead-212 (alpha emitter) in small cell lung cancer.
• Only Oral Formulation of Levosimendan in Phase 3: If successful, oral levosimendan would be the first oral formulation of an established IV heart failure inotrope to reach approval.
• Eight Companies With Simultaneous Catalysts: A single session produced FDA clearances, clinical data, capital raises, compliance notices, buybacks, reverse splits, patent grants, and biocompatibility results across eight companies.
• Three Companies Face Compliance Challenges Simultaneously: Mdxhealth received a deficiency notice, NewGenIvf announced a reverse split, and Tenon Medical raised dilutive capital despite positive FDA clearance, all on the same day.
• Strategic IP Milestone: Galmed Pharmaceuticals' (NASDAQ: GLMD) USPTO Notice of Allowance strengthens the company's negotiating position in future licensing talks.
Please wait processing your request...